<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780750</url>
  </required_header>
  <id_info>
    <org_study_id>head and neck cancers</org_study_id>
    <nct_id>NCT04780750</nct_id>
  </id_info>
  <brief_title>Concurent Chemoradiotherapy in Head and Neck Cancers</brief_title>
  <official_title>Phase III Study Comparing Concurrent Chemoradiotherapy With Weekly Docitaxel Plus Cisplatin Versus the Standard Concurrent Radiotherapy With Cisplatin in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and toxicities of the combination between weekly docitaxel and&#xD;
      cisplatin (every3 week) concurrent with radiation versus the standard concurrent&#xD;
      chemoradiotherapy with high dose cisplatin (100mg\m2) for locally advanced HNSCC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Head and neck cancer is the eighth most common cancer in the United States . For locally&#xD;
      advanced HNSCC, concurrent chemoradiotherapy (chemo-RT) is the standard treatment established&#xD;
      with multiple randomized trials . The survival benefit of chemo-RT in locally advanced HNSCC&#xD;
      has been confirmed by meta-analyses, which revealed a 19% reduction in mortality and an&#xD;
      absolute survival benefit of 8% at 5years when chemotherapy was administered concurrently&#xD;
      with radiation Despite incremental improvements in local regional control and survival in&#xD;
      HNSCC patients treated with chemo-RT, a substantial fraction of patients suffer persistent or&#xD;
      recurrent diseases. Combining novel agents with radiation therapy therefore remains of great&#xD;
      interest to further improving the treatment outcomes of HNSCC .&#xD;
&#xD;
      Cisplatin is the most commonly used chemotherapeutic agent given concurrently with radiation.&#xD;
      However, introduction of additional effective radiosensitizing agents is urgently needed. A&#xD;
      significant percentage of patients appropriate for definitive concurrent chemo-RT are not&#xD;
      candidates for cisplatin based treatment.&#xD;
&#xD;
      Furthermore, recent data have emerged that cisplatin might not be the most optimal cytotoxic&#xD;
      radiosensitizing agent when addition of novel targeted agents to concurrent chemo-RT is&#xD;
      evaluated.&#xD;
&#xD;
      Radiation Therapy Oncology Group (RTOG) 0234 is a phase II randomized clinical trial&#xD;
      evaluating postoperative radiation plus concurrent docetaxel and cetuximab versus&#xD;
      postoperative radiation plus cisplatin and cetuximab for high-risk HNSCC after surgery. The&#xD;
      results showed an impressive improvement in overall survival and disease-free survival of the&#xD;
      docetaxel arm compared to the cisplatin arm (79% versus 69% and 66% versus 57% respectively .&#xD;
      These results are pointing to the possibility that a non-cisplatin based regimen chemo-RT&#xD;
      should be explored for further development of novel targeted agents and led to a recently&#xD;
      opened phase III randomized RTOG trial, RTOG 1216, which compares postoperative radiation&#xD;
      with concurrent cisplatin versus docetaxel versus docetaxel and cetuximab for high-risk HNSCC&#xD;
      patients . docetaxel appears to have active antitumor activity in advanced SCCHN . In&#xD;
      preclinical studies, docetaxel leads to tumor cell reoxygenation and mitotic arrest with&#xD;
      potent radiosensitization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>locoregional recurrence free survival in months</measure>
    <time_frame>1 years</time_frame>
    <description>comparison of the locoregional recurence free survival in both arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>overall survival in months in both arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Arm A concurrent chemoradiotherapy with weekly docitaxel and cisplatin every 3 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\m2) and cisplatin (80mg\m2 every 3 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B :concurrent chemoradiotherapy with cisplatin every 3 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B (standard regimen):concurrent chemoradiotherapy with cisplatin (100mg\m2 every 3 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\m2) and cisplatin (80mg\m2 every 3 weeks)</description>
    <arm_group_label>Arm A concurrent chemoradiotherapy with weekly docitaxel and cisplatin every 3 weeks</arm_group_label>
    <arm_group_label>Arm B :concurrent chemoradiotherapy with cisplatin every 3 weeks</arm_group_label>
    <other_name>taxoter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pathologically confirmed squmous cell carcinoma performance status 0-1 adequte renal&#xD;
             and hepatic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  poor performance status&#xD;
&#xD;
          -  impaired renal or hepatic function&#xD;
&#xD;
             =Squamous cell carcinoma of salivary gland,parotid and paranasal carcinomas were&#xD;
             --0excluded from the study&#xD;
&#xD;
          -  patients with â‰¥ grade 2 pre-existing peripheral neuropathy, history of allergic&#xD;
             reactions to the chemotherapeutic agents, and uncontrolled intercurrent diseases as&#xD;
             well as HIV positive patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>doAA ABDELALEEM, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>doaa abdelaleem alsayed, MASTER</last_name>
    <phone>01142753583</phone>
    <email>dodoalemo@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>amal rayan ibrahim, Master</last_name>
    <phone>01022454482</phone>
  </overall_contact_backup>
  <link>
    <url>https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.3322/caac.21153</url>
    <description>Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.</description>
  </link>
  <link>
    <url>https://www.researchgate.net/profile/Etienne_Bardet/publication/8975191_Final_Results_of_the_94-01_French_Head_and_Neck_Oncology_and_Radiotherapy_Group_Randomized_Trial_Comparing_Radiotherapy_Alone_With_Concomitant_Radiochemotherapy_in_Advanced-Stage_Oropharynx_Carcinoma/links/568cf18c08aeb488ea31c87c.pdf</url>
    <description>Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharyngeal carcinoma. J Clin Oncol. 2004; 22:69-76.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3577950/</url>
    <description>Concurrent chemotherapy and radiotherapy for organ preservation in advanced larynx cancer. N Engl J Med. 2003; 349:2091-2098.</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0140673600900114</url>
    <description>Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data. Lancet. 2000; 355:949-955.</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0167814009001881?casa_token=egrt4XMYwcEAAAAA:afO0ENCle2OMP81FOq42fUT9LhyBZL2NVvTf8DY3munppWHoZJyLLr2Ts1gfuTTGIxW5I4tAxQTo</url>
    <description>Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92:4-14.</description>
  </link>
  <link>
    <url>https://www.redjournal.org/article/S0360-3016(09)01099-2/abstract</url>
    <description>Phase II Randomized Trial of Postoperative Chemoradiation Plus Cetuximab for High-risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234). Int J Rad Onc. 2009;75(3):S14-15.</description>
  </link>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/abs/10.1002/hed.25359</url>
    <description>RTOG 1216</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0923753419453088</url>
    <description>Role of taxoids in head and neck cancer. Oncologist 2000;5:199-208</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0923753419570508</url>
    <description>Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999;10:119-22</description>
  </link>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/abs/10.1002/hed.10232</url>
    <description>Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 2003;25:152-67</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>doaa abd elaleem alsayed mohamed</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

